Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder of systemic microthrombosis and organ ischemia. The etiology of chronic cerebrovascular outcomes in iTTP survivors is largely unknown. In this pilot study, we measured blood–brain barrier (BBB) permeabili...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945621/ https://www.ncbi.nlm.nih.gov/pubmed/34521110 http://dx.doi.org/10.1182/bloodadvances.2021005317 |
_version_ | 1784673997633355776 |
---|---|
author | Huang, Shih-Han Susan Pavenski, Katerina Lee, Ting-Yim Jurkiewicz, Michael T. Bharatha, Aditya Thiessen, Jonathan Dale St. Lawrence, Keith Théberge, Jean Mandzia, Jennifer Barth, David Licht, Christoph Patriquin, Christopher Jordan |
author_facet | Huang, Shih-Han Susan Pavenski, Katerina Lee, Ting-Yim Jurkiewicz, Michael T. Bharatha, Aditya Thiessen, Jonathan Dale St. Lawrence, Keith Théberge, Jean Mandzia, Jennifer Barth, David Licht, Christoph Patriquin, Christopher Jordan |
author_sort | Huang, Shih-Han Susan |
collection | PubMed |
description | Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder of systemic microthrombosis and organ ischemia. The etiology of chronic cerebrovascular outcomes in iTTP survivors is largely unknown. In this pilot study, we measured blood–brain barrier (BBB) permeability in patients with iTTP at the start of remission and 6 months later. This prospective pilot study included 7 adult patients with incident iTTP. Eligibility criteria included ADAMTS13 activity < 10% and detectable inhibitor at diagnosis. Patients were recruited from London Health Sciences Centre in Canada (2017-2019) within 3 days of hospital admission and followed for 6 months after remission (defined as normalization of platelet count and lactate dehydrogenase with no clinical signs or symptoms of microvascular injury for more than 30 days after the last plasma exchange). All patients had cerebral computed tomography perfusion scans with BBB permeability surface product measurements. Patients (5 women, 2 men) had a mean age of 48 years (range, 21-77 years). At diagnosis, patients had a mean platelet count of 22 (standard deviation [SD], 25) × 10(9)/L. At the start of remission, mean BBB permeability surface product was 0.91 (0.30) mL/min/100 g. Six months later, the mean permeability surface product was 0.56 (0.22) mL/min/100 g, with a mean difference of −0.312 mL/min/100 g (95% confidence interval: −0.4729 to −0.1510; P = .0032). In this pilot study of patients with iTTP, pathologically increased BBB permeability was evident, and although there was some improvement, this persisted 6 months after remission. Future work will explore the chronicity of these findings and their clinical implications. |
format | Online Article Text |
id | pubmed-8945621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-89456212022-03-29 Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study Huang, Shih-Han Susan Pavenski, Katerina Lee, Ting-Yim Jurkiewicz, Michael T. Bharatha, Aditya Thiessen, Jonathan Dale St. Lawrence, Keith Théberge, Jean Mandzia, Jennifer Barth, David Licht, Christoph Patriquin, Christopher Jordan Blood Adv Platelets and Thrombopoiesis Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder of systemic microthrombosis and organ ischemia. The etiology of chronic cerebrovascular outcomes in iTTP survivors is largely unknown. In this pilot study, we measured blood–brain barrier (BBB) permeability in patients with iTTP at the start of remission and 6 months later. This prospective pilot study included 7 adult patients with incident iTTP. Eligibility criteria included ADAMTS13 activity < 10% and detectable inhibitor at diagnosis. Patients were recruited from London Health Sciences Centre in Canada (2017-2019) within 3 days of hospital admission and followed for 6 months after remission (defined as normalization of platelet count and lactate dehydrogenase with no clinical signs or symptoms of microvascular injury for more than 30 days after the last plasma exchange). All patients had cerebral computed tomography perfusion scans with BBB permeability surface product measurements. Patients (5 women, 2 men) had a mean age of 48 years (range, 21-77 years). At diagnosis, patients had a mean platelet count of 22 (standard deviation [SD], 25) × 10(9)/L. At the start of remission, mean BBB permeability surface product was 0.91 (0.30) mL/min/100 g. Six months later, the mean permeability surface product was 0.56 (0.22) mL/min/100 g, with a mean difference of −0.312 mL/min/100 g (95% confidence interval: −0.4729 to −0.1510; P = .0032). In this pilot study of patients with iTTP, pathologically increased BBB permeability was evident, and although there was some improvement, this persisted 6 months after remission. Future work will explore the chronicity of these findings and their clinical implications. American Society of Hematology 2021-10-22 /pmc/articles/PMC8945621/ /pubmed/34521110 http://dx.doi.org/10.1182/bloodadvances.2021005317 Text en © 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
spellingShingle | Platelets and Thrombopoiesis Huang, Shih-Han Susan Pavenski, Katerina Lee, Ting-Yim Jurkiewicz, Michael T. Bharatha, Aditya Thiessen, Jonathan Dale St. Lawrence, Keith Théberge, Jean Mandzia, Jennifer Barth, David Licht, Christoph Patriquin, Christopher Jordan Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study |
title | Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study |
title_full | Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study |
title_fullStr | Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study |
title_full_unstemmed | Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study |
title_short | Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study |
title_sort | blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study |
topic | Platelets and Thrombopoiesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945621/ https://www.ncbi.nlm.nih.gov/pubmed/34521110 http://dx.doi.org/10.1182/bloodadvances.2021005317 |
work_keys_str_mv | AT huangshihhansusan bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT pavenskikaterina bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT leetingyim bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT jurkiewiczmichaelt bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT bharathaaditya bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT thiessenjonathandale bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT stlawrencekeith bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT thebergejean bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT mandziajennifer bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT barthdavid bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT lichtchristoph bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy AT patriquinchristopherjordan bloodbrainbarrierpermeabilityinsurvivorsofimmunemediatedthromboticthrombocytopenicpurpuraapilotstudy |